Targeting chronic mucus hypersecretion in respiratory diseases - focus on OPEP devices

Area of Science:

• Pulmonology and Respiratory Medicine
• Pharmacology
• Medical Devices

Background:

• Chronic respiratory diseases (CRDs) present a growing health challenge, particularly in India.
• Chronic mucus hypersecretion (CMH) is a key characteristic of many CRDs, leading to impaired mucociliary clearance, frequent infections, and disease advancement.
• Effective airway clearance is crucial for managing CRDs and improving patient outcomes.

Purpose of the Study:

• To review the prevalence and impact of CMH in various CRDs.
• To evaluate pharmacological (N-acetylcysteine, erdosteine) and non-pharmacological (OPEP devices) therapies for CMH.
• To provide therapeutic recommendations for clinicians managing CMH.

Main Methods:

• Comprehensive literature review of published evidence on CMH therapies.
• Focus on the mechanisms of action for mucoactive drugs and OPEP devices.
• Analysis of clinical evidence supporting the efficacy of these interventions.

Main Results:

• N-acetylcysteine and erdosteine are commonly used mucoactive agents in India for CMH.
• Oscillating positive expiratory pressure (OPEP) devices offer a non-pharmacological approach to enhance mucus clearance via positive pressure and oscillation.
• Both mucoactive agents and OPEP devices demonstrate potential in preventing infections, reducing exacerbations, and improving lung function and quality of life.

Conclusions:

• CMH significantly impacts CRD progression and necessitates effective airway clearance strategies.
• A combination of mucoactive drugs and OPEP devices can be beneficial in managing CMH.
• Evidence supports the use of these therapies to improve clinical outcomes in patients with CRDs.